|
Status |
Public on Jan 19, 2018 |
Title |
B17-IP1 |
Sample type |
RNA |
|
|
Source name |
BL case B17
|
Organism |
Homo sapiens |
Characteristics |
tissue: Fresh-frozen primary BL tumor tissue age: 12 gender: female
|
Treatment protocol |
CD19+ B cells were sorted by magnetic-activated cell sorting (MACS) from tonsil tissue samples of three donors between three and nine years old. Briefly, a freshly prepared tonsillar cell suspension was prepared and enriched for CD19+ cells using CD19-beads and LS columns (both Miltenyi Biotec, Leiden, The Netherlands). For BL tumor tissues, immunoprecipitation of AGO2-containing RISC complexes was performed on fifty 10 uM tissue sections of two fresh-frozen primary BL tumors.
|
Extracted molecule |
total RNA |
Extraction protocol |
miRNeasy Micro/Mini Kit (Qiagen)
|
Label |
Cy5
|
Label protocol |
Cy5 labeled using 50-100ng total RNA in combination with the LowInput QuickAmp Labelling Kit, Cyanine 5 CTP Dye Pack and RNA Spike-In kit (all Agilent Technologies). Each sample was labeled and hybridized in duplicate.
|
|
|
Hybridization protocol |
Overnight hybridization at 65oC on Agilent-050524 SurePrint G3 Custom Human 8x60K according to the manufacturers instructions
|
Scan protocol |
Agilent DNA Microarray Scanner, Agilent Feature Extraction software version 10.7.3.1.
|
Description |
AGO2-RIP was performed on fifty 10 uM tissue sections mRNA and lncRNA expression analysis_BL case B17_AGO2IP fraction_1
|
Data processing |
GeneSpring GX 12.5 software (Agilent Technologies); quantile normalization without base line transformation.
|
|
|
Submission date |
Nov 24, 2017 |
Last update date |
Jan 24, 2018 |
Contact name |
Agnieszka Dzikiewicz-Krawczyk |
E-mail(s) |
krawczyk@man.poznan.pl
|
Phone |
+48616579219
|
Organization name |
Institute of Human Genetics, Polish Academy of Sciences
|
Street address |
Strzeszynska 32
|
City |
Poznan |
ZIP/Postal code |
60-479 |
Country |
Poland |
|
|
Platform ID |
GPL18641 |
Series (1) |
GSE107325 |
Microarray analysis to identify miRNA targetome of primary Burkitt lymphoma tumors in comparison to normal CD19+ B cells |
|